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Case presentation
A 48-year-aid man developed edema 5.5 years ago and was found to
have idiopathic nephrotic syndrome. Blood pressure, renal function,
and serum complement were normal; urine protein excretion was 12 g
daily; no hematuria was present. Open renal biopsy disclosed normal
glomeruli by light microscopy, with the exception of one obsolescent
glomerulus. Immunofluorescent studies demonstrated no deposition of
IgG, 1gM, IgA, complement (C3), or fibrinogen in glomeruli, and
electron microscopic evaluation revealed only diffuse epithelial cell foot
process obliteration. Because of the lack of significant glomerular
findings other than global sclerosis of one of 15 glomeruli by light
microscopic evaluation, probable minimal-change disease was diag-
nosed. A 4-month course of treatment with 120mg of prednisone given
every other day did not affect urine protein excretion. Furosemide was
prescribed for edema. Hypertension and microscopic hematuria ap-
peared 4.5 years ago, and the serum creatinine level rose to 1.7 mg/dl.
Methyldopa was prescribed, and 125 mg of cytoxan was given daily for
4 months without producing improvement in renal function. During the
next 1.5 years, the patient's renal function gradually deteriorated.
Maintenance hemodialysis was begun 3 years ago. During dialysis
therapy, the patient's daily urine volume remained approximately 1
liter; it contained 9 g of protein; and the serum albumin remained at 3.0
g/dl. Urine sediment contained 50 red blood cells per high-power field.
The patient received a one-haplotype matched kidney transplant from
his sister 2.5 years ago. Mixed lymphocyte culture revealed a stimula-
tion index of 5.46 and a relative response of 17%. Pretransplant donor
evaluation included three 24-hour urine collections, which contained 1,
80, and 100 mg of protein, respectively. Prednisone and azathioprine
were given for immunosuppression in standard doses. Postoperatively,
the serum creatinine level fell to 1.5 mg/dl, but urine protein excretion
rose promptly to 7 g/day. On the fifth postoperative day, renal function
deteriorated because of presumed allograft rejection. The patient re-
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ceived 1 g of methylprednisolone intravenously each day for 3 days, and
he required two hemodialysis treatments. During the next month,
serum creatinine declined to 1.2 mg/dl. One month later renal function
again deteriorated and a second course of "pulse" methylprednisolone
therapy was given. The serum creatinine level subsequently stabilized
at 1.8 mg/dl, and urine protein excretion remained at 5 to lOg daily.
Two years ago, renal function began to decline slowly and progress-
ively. Hypertension and edema reappeared and were treated with
propranolol and furosemide. Asymptomatic staphylococcal bacteriuria
was eradicated with penicillin. A third course of "pulse" methylpredni-
solone (1.5 g) administered 1.5 years ago failed to prevent the progres-
sion of renal failure. A percutaneous renal biopsy revealed a total of 9
glomeruli, 2 of which were globally sclerosed and 2 of which demon-
strated segmental collapse and sclerosis without increased cellularity.
The remaining glomeruli either were normal or had minimal evidence of
ischemic damage. Mild interstitial cellular rejection was present with
foci of tubular invasion. There was no evidence of vascular rejection.
Immunofluorescent studies demonstrated focal, segmental, glomerular
deposition of 1gM and complement (C3 and C4) without significant
deposits of IgG, IgA, or fibrinogen. There was also focal granular
deposition of IgG, C3, and C4 on tubular basement membranes.
Ultrastructural studies revealed segmental glomerular capillary base-
ment membrane collapse and sclerosis with insudative deposits in
damaged areas. No characteristic glomerular rejection changes were
identified. In the absence of ultrastructural evidence of typical changes
of "rejection glomerulopathy," and the absence of vascular rejection,
focal segmental sclerosing glomerulonephropathy was diagnosed. Seg-
mental changes could not be demonstrated in the initial biopsy, but
because of the clinical course and these allograft glomerular findings,
recurrent focal and segmental sclerosis was considered a possibility
rather than de novo disease.
Renal failure worsened over the following 6 months and urine protein
excretion remained at 5 to 10 g daily. Hemodialysis was reinstituted 1
year ago because of fluid overload. Urine output declined to less than 30
ml daily and serum albumin rose to 4.9 g/dl.
Despite the risk of recurrence of renal disease, the patient chose to
undergo cadaveric renal transplantation because he was unhappy with
dialysis. He received five random donor blood transfusions during the
next 6 months. Four months ago, he received a kidney from a 5-year-old
child. Immunosuppressive therapy included standard doses of predni-
sone and azathioprine. On the second postoperative day, urine volume
was 400 ml and it contained 3.4 g of protein and many red blood cells.
The patient remained oliguric for 10 days and required repeated
hemodialysis. While oliguric, daily urine protein excretion was 200 to
600 mg. On the 12th postoperative day, his temperature rose to 101° F,
and acute allograft rejection was diagnosed. He received 1.5 g of
methylprednisolone over 3 days and radiation (450 rads) to the trans-
planted kidney.
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Table 1. Histopathologic variants of minimal-change glomerulopathy
Minimal changes
Focal sclerotic changes
Global
With tubular atrophy
Without tubular atrophy
Segmental
With tubular atrophy
Without tubular atrophy
Mesangial proliferation
Diffuse
Segmental
Renal function improved and proteinuria increased over the next
week. By the end of the third postoperative week, urine protein
excretion was 3 to 4 g/day.
During the following months, renal function continued to improve. At
the time of his most recent examination, the patient felt well and had
returned to work half-time. Medications included 50 mg of prednisone,
100 mg of azathioprine, 100 mg of hydralazine, 1.6 mg of clonidine, and
240 mg of furosemide daily. Blood pressure was 180/90 mm Hg, and he
had 4+ peripheral edema. Serum creatinine was 2.4 mg/dl, and serum
albumin was 2,8 g/dl. Twenty-four hour urine protein excretion was 4 g,
and urinalysis revealed 20 to 30 red blood cells per high-power field; no
casts were present.
Discussion
DR. EDMUND J. LEwis (Profrssor of' Medicine, Rush Medi-
cal College, and Director, Section of Nephrology, Rush-Pres-
byterian-St. Luke's Medical Center, Chicago, Illinois): The
patient we are discussing today had a glomerular lesion associ-
ated with the idiopathic nephrotic syndrome, which progressed
to chronic renal failure in approximately 2.5 years. He had two
kidney transplants, both of which were accompanied by rejec-
tion crises, poor renal function, and significant proteinuria. His
course illustrates the difficulty we often have in understanding
glomerular damage and dysfunction when it occurs following
renal transplantation.
To consider the potential insults that could have led to
glomerular damage in the renal allograft, we first will turn our
attention to the patient's original disease. We are told that the
patient had an open renal biopsy when renal function was
normal and when 24-hour urine protein excretion was 12 g. The
biopsy showed no abnormality by light microscopy, and immu-
nofluorescent examination did not demonstrate immune depos-
its. One glomerulus was interpreted as having global sclerosis.
On the basis of these data, the histologic diagnosis was minimal-
change glomerulopathy. Yet the patient did not respond to high-
dose prednisone therapy, as we would have expected. His
proteinuria continued, he developed hypertension and micro-
scopic hematuria, and his renal function progressively deterio-
rated. These responses led to the need for hemodialysis approx-
imately 2.5 years after the nephrotic syndrome first became
manifest.
The chronic progressive loss of renal function in this patient
most likely indicates progression of the glomerular lesion.
Other intercurrent events that can account for acutely dimin-
ished renal function in patients with the nephrotic syndrome do
not fit this patient's clinical course. Acute renal failure with
allergic interstitial nephritis can be associated with diuretic
therapy [1, 2]. Acute renal failure, which may be irreversible,
also has been reported in nephrotic patients with severe hypoal-
buminemia [3]. These possibilities do not appear germane to
this patient and I will not consider them further. More pertinent
is the question of how a glomerular lesion appearing as innocent
as that found in the patient's first renal biopsy could progress to
end-stage renal failure.
Clinical significance of the histologic variants of
minimal-change glomerulopathy
Let us first consider the variants of minimal-change glomeru-
lopathy (Table 1). Dr. Arnold Rich is given credit for initially
demonstrating a significant morphologic variant. His 1957 paper
described the morphologic entity of focal and segmental glomer-
ular sclerosis (FSGS) [4]. Rich made his observations on
autopsy specimens from 20 children who had nephrotic syn-
drome at the time of death; 11 of these patients died of sepsis
and 9 died of uremia. He thus observed the lesions at dif-
ferent stages of evolution and noted that in the earliest phases
they tended to appear in the glomeruli adjacent to the cortico-
medullary junction but that superficial glomeruli also were
involved in more advanced cases. The significance of this
observation was not immediately appreciated. A few years
later, however, the lesion again was described in renal biopsy
specimens from patients with the nephrotic syndrome [5, 6].
The clinicopathologic importance of the lesion of focal and
segmental glomerular sclerosis and hyalinosis (FSGS/H) was
identified in the International Study of Kidney Disease in
Children [7] (Figs. IA, 1B). The investigators noted that focal
and segmental glomerular sclerosis was associated with unre-
sponsiveness to corticosteroid therapy, and they placed the
lesion in a category separate from that of steroid-responsive,
minimal-change glomerulopathy. The progression of FSGS/H
to renal failure was then recognized [6, 8].
Diffuse mesangial hypercellularity constitutes a second mor-
phologic variant of minimal-change glomerulopathy. Patients
with this lesion generally have a poorer prognosis than do those
with minimal-change glomerulopathy. Waldherr et al studied 38
patients with diffuse mesangial proliferation and the idiopathic
nephrotic syndrome, and they categorized these patients ac-
cording to the concomitant presence of FSGS/H [9]. Approxi-
mately 20% of the patients with pure mesangial cell prolifera-
tion had either a spontaneous or steroid-induced remission,
whereas 28% had a progressive loss of renal function. Among
20 patients with both mesangial cell proliferation and FSGS/H,
none responded to steroid therapy, and one-half had a progres-
sive decline of renal function. In addition, the majority of
patients with only mesangial hypercellularity on the first of two
biopsies manifested FSGS/H in the second specimen. These
observations lead us to question whether FSGS/H results from
progression of mesangial hypercellularity; the query remains
controversial. Nevertheless, both subcategories of minimal-
change glomerulopathy frequently are associated with progres-
sive glomerular sclerosis and renal failure. Schoeneman, Ben-
nett, and Greifer confirmed the serious prognostic implications
of both mesangial hypercellularity and focal and segmental
sclerosis; one-third of their patients with these lesions devel-
oped renal failure within 3 to 6 years [10].
These histologic variations, although frequently subtle, carry
important prognostic significance. Neither mesangial hypercel-
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Fig. 1A. Photomicrograph illustrating the segmental character of focal and segmental glomerular sclerosis and hyalinosis. There is collapse of the
capillary tuft and scarring with adhesion of the scarred portion of the glomerulus to Bowman's capsule. The portion of the glomerulus from
approximately II o'clock to 2 o'clock is essentialy normal. Other glomeruli in the biopsy were completely normal or showed mesangial
hypercellularity (methenamine silver stain). Fig. lB. Immunofluorescence photomicrograph of a glomerulus stained for the presence of 1gM
reveals this protein in a scarred area of the glomerular tuft. The portion of the glomerular tuft to the right of the photograph was histologically nor-
mal and did not contain 1gM. C3 was present in the same pattern. The deposition of these two proteins is often seen in FSGS/H and is believed to be
a secondary phenomenon.
lularity nor segmental sclerosis was noted in the first biopsy
from the patient we are discussing today. We must realize,
however, that the tissue obtained at open renal biopsy often
consists only of superficial cortex, and that segmental sclerosis
within juxtamedullary glomeruli easily could be missed. This
patient's course is entirely compatible with FSGS/H.
The patient's immediate posttransplant course was character-
ized by proteinuria and an acute rejection episode that respond-
ed to therapy. One of the complicating features in this patient is
that his own kidneys were left in place. As is often the case in
patients with FSGS/H, a large amount of protein can be
excreted from native kidneys despite virtually negligible renal
excretory function. We cannot be certain therefore that the
pronounced proteinuria necessarily represented allograft dys-
function. We are told that the patient continued to excrete 5 to
10 g/day of urine over a 2-year period. Given the likelihood of
total cessation of his own renal function and the subsequent
information regarding a slow and progressive decline of the
allograft's function, I conclude that ultimately the proteinuria
derived from the allograft.
Differential diagnosis of nephrotic-range proteinuria ftillowing
renal transplantation
Proteinuria commonly occurs immediately afier transplanta-
tion. The average daily output is as high as 2 to 3.5 g/day during
the first week, even when there is no overt rejection [11—141.
The pattern of protein excretion in transplant patients reflects
both excessive glomerular leakage and decreased tubular reab-
sorption of proteins. Hence, elevated albumin excretion indi-
cates excessive filtration of high-molecular-weight plasma pro-
teins, and elevated 3-2 microglobulin excretion reflects de-
creased reabsorption of low-molecular-weight proteins by
damaged tubules [141. In patients with stable renal function, we
would expect total protein excretion to decrease to less than 0.5
g/day within the first few months. The presence of nephrotic-
range proteinuria after the first 2 weeks following transplanta-
tion thus signals the development of abnormally altered glomer-
ular permeability and suggests the presence of one or another of
the glomerulopathies that can adversely affect renal transplants
(Table 2).
Transplant rejection glomerulopathy. Proteinuria and the
nephrotic syndrome are well-established manifestations of
chronic rejection. In the late 1960s, Harlin et al called attention
to the relatively common occurrence of proteinuria in excess of
3 g/day in patients with a history of multiple acute or chronic
rejection episodes [151. The onset of proteinuria among these
patients varied from 3 to 12 months after transplantation.
Histologic studies of Porter et al provided further evidence that
glomerular changes were common in renal allografts (16].
Amorphous subendothelial material and thickening of the
glomerular basement membrane were the most frequently de-
scribed abnormalities. A significant association was noted
between histoincompatibility and the amount of glomerular
damage. We should note that our patient had only a 1-haplotype
match with his donor and that the results of the mixed lympho-
cyte culture tests revealed a significant mismatch at the HLA-D
locus. Thus, in this patient, the glomerulus might have been
damaged simply by a chronic rejection reaction. Cheigh et al
described proteinuria and the nephrotic syndrome in 24 of 81
transplant patients studied [17]. The original disease leading to
renal failure was nonimmunologic in 9 of these 24 patients.
These studies established that the immunologic lesion of trans-
plant rejection glomerulopathy is associated with a substantial
amount of proteinuria. The onset of severe proteinuria before
the sixth month post transplantation, however, is unusual in
patients in whom the original lesion was not in the glomerulus.
Matthew and coworkers studied 27 patients who developed
glomerular lesions after transplantation. In 8, the original
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Table 2. The glomerulopathies of allotransplantation
Transplant rejection glomerulopathy
Persistent nephritogenic stimulus
Identifiable immunologic process
1. Anti-GBM disease
2. Mesangial IgA nephropathy
3. Membranous glomerulonephritis
Glomerulopathy of undetermined pathogenesis
I. FSGS/H
2. Glomerulopathy of vesicoureteral reflux
De novo process
I. Postinfectious (hepatitis B)
2. Acute serum sickness (horse anti-human lymphocyte globulin)
Donor glomerulopathy
a Adapted from Ref. 22.
GBM refers to glomerular basement membrane.
Table 3. Onset of proteinuria and the nephrotic syndrome in allograft
recipients
Focal and segmental glomerular sclerosis
Onset of
Progression nephrotic-
to renal range
Age of patient failure proteinuria
Author years %'ears months
Hoyera 7.5 2
2 2 1.5
22 6 5
Malekzadehh 9 6 9
I <I
1.5 9 <I
Data from Ref. 20.
b Data from Ref. 25.
No history of glomerular disease
disease was not glomerulonephritis [18]. The pattern of his-
tologic change in the allograft was interpreted as mesangiocapil-
lary glomerulonephritis in 7 of these 8 patients. This lesion is
characterized by mesangial expansion, hypercellularity, and
circumferential interposition of mesangial material between the
endothelial cells and the glomerular basement membrane. Sub-
endothelial electron-dense deposits are sometimes also present.
Fluorescence microscopy may reveal mesangial deposits of
1gM, C3, and fibrin in the mesangium and in peripheral capillary
loops, but IgG and other complement components are less
consistently present. Varying degrees of segmental and global
sclerosis may accompany this lesion. Proteinuria was present in
all patients studied by Matthew, and 7 of 8 had either deteriorat-
ing renal function or established renal failure. The authors
observed that vesicoureteral reflux occurred much more often
in patients who developed glomerular lesions in the transplant-
ed kidney. I will comment on this later.
To summarize, profuse proteinuria and the nephrotic syn-
drome can result from a glomerular insult that derives from
rejection phenomena. This lesion is found in patients who
originally did not have glomerulonephritis as frequently as it
appears in those who did [15, 17, 18]. It seems to develop more
frequently in patients who have several acute rejections or
evidence of chronic rejection [19]. In addition, HLA incompati-
bility [16] and HLA presensitization [18] both have been
reported more frequently in patients developing this
glomerulopathy.
The histologic and clinical manifestations of this glomerular
lesion, which appears to be caused by a transplantation rejec-
tion mechanism, is frequently indistinguishable from the lesion
associated with recurrence of FSGS/H in the allograft [18], and
I now would like to discuss the latter lesion.
Recurrence of FSGSIH in the allograft. Recurrence of the
nephrotic syndrome in patients with FSGS/H is well docu-
mented [20—26]. Moreover, when the interval between the onset
of the nephrotic syndrome and the development of end-stage
renal disease is less than 3 years, the risk of recurrence in the
allograft can be as high as 50%; in contrast, the risk of
recurrence is only 10% to 20% when this interval exceeds 3
years [22, 23]. When FSGSIH recurs, massive proteinuria
usually develops within days of the transplant [22] (Table 3).
Renal biopsy shortly after transplantation reveals the lesion of
minimal-change glomerulopathy, with diffuse glomerular epi-
thelial cell foot process fusion [20]. The segmental sclerosis is
readily demonstrated in later biopsies, however. The one-year
survival of grafts in which FSGSIH recurs appears to be
significantly lower than that for unaffected allografts. The risk
in subsequent transplants is variable. Nephrotic syndrome has
been reported in successive grafts [21]; however, there are
cases in which a subsequent transplanted kidney did not
manifest the disease [25, 26].
De novo renal disease. A third possible explanation for
proteinuria in the renal allograft is the development of a de novo
process in the kidney, for example, glomerulonephritis follow-
ing hepatitis B infection [27]. We have no information that
would lead us to suspect an independent lesion in the patient
under discussion today. An additional possibility is that some
intercurrent complication, such as renal vein thrombosis, might
explain the patient's recurrent proteinuria. However, as with
primary forms of glomerulonephritis, renal vein thrombosis is
likely a secondary phenomenon and not the cause of the
proteinuria [28, 29].
Clues to the clinical differentiation of transplant glomerulo-
pathy and recurrent FSGS/H sometimes can be derived from
the time of onset of proteinuria and its persistence (Table 3). As
in this patient, however, the data can be inconclusive. Another
approach to the differentiation between transplant rejection
Urine
protein
giday
12.8
7.6
8.5
12
8
3.8
Patient's diagnosis
Onset of
nephrot ic-
range
proteinuria
months
Medullary cystic disease
Congenital urinary tract deformity
Chronic pyelonephritis
Polycystic renal disease
Medullary cystic disease
Congenital urinary tract deformity
Congenital urinary tract deformity
Congenital urinary tract deformity
Congenital urinary tract deformity
Urine
protein
g/day
6
3
3
4
10
3
3
4
4
50
48
23
12
9
7
20
6
Data from Ref. 17.
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Fig. 2. Differentiation of tubular proteinuria from giomerular protein-
uria. Thedetermination of the fractional excretion of /3-2 microglobulin
can be of value in determining whether the protein appearing in the
urine is the result of abnormal glomerular permeability or decreased
tubular reabsorption of protein. In the normal situation, little albumin is
filtered; however, /3-2 microglobulin is of low molecular weight, and
small amounts freely cross the glomerular capillary wall. When protein-
uria is due to a glomerular defect (center), both high-molecular-weight
(albumin) and low-molecular-weight (/3-2 microglobulin) proteins are
excreted in the urine. In the presence of a tubular defect, however
(right), the absence of the normal absorption of /3-2 microglobulin
results in elevated fractional excretion of this protein. As noted in the
text, this differentiation can be of value in determining whether protein-
uria is due to the tubulo-interstitial lesion of transplant rejection.
(Illustration copyright Pharmacia Diagnostics AB, Uppsala, Sweden)
glomerulopathy and a recurrent glomerular lesion is evaluation
of the renal handling of low-molecular-weight proteins, particu-
larly /3-2 microglobulin [14, 30] (Fig. 2). Beta-2 microglobulin is
a protein released from cell surfaces. It has a molecular weight
of 11,800 daltons and is freely filtered at the glomerulus.
Approximately 150 mg of /3-2 microglobulin is filtered daily.
Normally less than 0.1% of the filtered /3-2 microglobulin
appears in the final urine. Renal diseases that affect tubular
function cause decreased reabsorption of this protein and hence
it appears in the urine in increased quantities. This phenomenon
of "tubular proteinuria" contrasts with the findings in a disease
characterized by a glomerular lesion with little or no tubular
involvement [31]. In the latter case, increased filtration of
albumin and high-molecular-weight proteins leads to protein-
uria but, because no change occurs in the permeability of the
glomerular basement membrane to /3-2 microglobulin, and
because there is little or no alteration of tubular function, the
rate of excretion of this protein does not change. When protein-
uria accompanies acute or chronic allograft rejection, fractional
excretion of /3-2 microglobulin is increased because of the
tubulointerstitial inflammatory reaction that accompanies the
immune response to the allograft [30]. A lesion that affects the
glomerulus primarily with little or no tubulointerstitial involve-
ment, as does early recurrent glomerular disease, would be
expected to cause proteinuria with a normal fractional excretion
of /3-2 microglobulin. This differential feature may be of value,
particularly early in the course of proteinuria. Unfortunately,
when the allograft has a concomitant primary glomerulopathy
and is rejected, or when tubular atrophy exists secondary to
advanced glomerular disease, the distinction may be impossible
to establish.
In addition to persistent proteinuria in the patient under
consideration, biopsy of the first allograft at 6 months revealed
severe segmental sclerosis in 2 glomeruli and global sclerosis in
2 glomeruli. Immunofluorescent microscopy demonstrated fo-
cal and segmental deposits of 1gM in damaged glomeruli. The
light microscopic and immunofluorescent findings are compati-
ble with either transplant rejection glomerulopathy or recur-
rence of the patient's original lesion, FSGSIH.
FSGSIH and other renal lesions
The recognition of FSGS!H on light microscopy is not
specific for the lesion associated with the idiopathic nephrotic
syndrome; the lesion can occur with other forms of glomerulo-
pathy as well [32]. It has been described in transplant patients
whose original disease was not due to FSGS/H [18, 19].
Ettenger et al described segmental glomerular sclerosis and
hyalinosis in 3 patients who had massive proteinuria and the
nephrotic syndrome associated with chronic rejection [19]. The
authors found the pathology in these cases identical to that of
FSGS/H. We therefore find no diagnostic comfort in the
demonstration of the lesion on light microscopy in the patient
we are discussing.
Kincaid-Smith has described lesions typical of FSGS/H in
patients with atrophic pyelonephritis and reflux nephropathy
[33]. In addition, she and her coworkers have suggested that
glomerular lesions, including those of FSGS/H, occur more
commonly in allografts complicated by vesicoureteral reflux
[18]. Many of these patients have substantial proteinuria. A
similar observation has been reported in 4 proteinuric children
with vesicoureteral reflux and either hydronephrosis or con-
tracted kidneys [34]. These children all had FSGS/H and a
persistent decline of renal function that did not change when the
urologic abnormality was corrected. One of the patients ulti-
mately received a successful transplant, and the authors make
no mention of a recurrent histologic lesion or proteinuria. The
pathogenetic relationship between vesicoureteral reflux and the
development of the glomerular lesion or proteinuria is not
known.
Although the recurrence of proteinuria in successive trans-
plants in today's patient and the histologic demonstration of
FSGS/H strongly suggests recurrence of the patient's original
lesion, we cannot with certainty exclude the possibility that this
condition resulted from chronic rejection. In addition, a compli-
cating factor such as vesicoureteral reflux might have contribut-
ed to his renal lesion.
Finally, let us consider the pathogenesis of recurrent
FSGS/H. The almost immediate onset of proteinuria in well-
documented cases of recurrent FSGS/H strongly suggests the
presence of a humoral factor responsible for altered glomerular
permeability [35, 36]. This observation raises the possibility
that an immunologic mechanism is operative. The coexistence
of glomerular mesangial hypercellularity and segmental sclero-
sis has led to the suggestion that the segmental scar may be the
result of inflammatory damage originating in the mesangium.
The data presented by Waldherr et al, who proposed that the
glomerular lesion evolves from mesangial proliferation to seg-
mental scarring of FSGS/H, support this notion [9]. The pres-
ence of 1gM in a mesangial distribution in some patients who
Norma'
Glomerular
defect
Tubular
defect
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Questions and answers
have the mesangial proliferative lesion associated with the
idiopathic nephrotic syndrome has led some authors to suggest
that this lesion is an immune-deposit disease [371 (Fig. 3). In
addition, the frequent finding of 1gM and C3 in sclerotic
segments of FSGSIH further suggests an immune nature of this
lesion [6] (Fig. 1B). Others have shown no relationship between
the demonstration of 1gM and response to therapy, relapse rate,
clinical course, or degree of mesangial hypercellularity [10, 38].
Thus, the suggestion that the lesion is immunologically mediat-
ed has little support.
An experimental model, namely, the rat that has undergone
subtotal nephrectomy, casts an interesting light on this other-
wise obscure subject. Such animals develop proteinuria and
progressive renal failure [39, 401. Following the onset of pro-
teinuria in the hypertrophic but otherwise normal glomeruli of
the remnant kidney, a glomerulosclerotic lesion develops that is
associated with renal failure and a progressive decline in
glomerular filtration rate. No alteration of glomerular polyanion
has been demonstrated in these kidneys [411. Therefore alter-
ations in glomerular hydrodynamics may well underlie the
progressive functional and morphologic changes noted in these
animals. These observations might be relevant to the explana-
tion of the progression of FSGS!H. The factor precipitating the
proteinuria remains unknown, however [42, 43].
In summary, the patient we have discussed exemplifies the
difficulty clinicians have in assessing glomerular lesions in
patients who have a complicated posttransplantation course.
Because it is likely that this patient's original lesion was
FSGS/H that ran a "malignant" course, we must suspect that a
recurrent glomerular process was responsible for the damage to
his two subsequent renal transplants [23, 44]. Of course, other
causes of glomerular injury, particularly chronic rejection, also
could explain the problem. We are left with a dramatic clinical
phenomenon—markedly altered glomerular permeability and
scarring—as the likely hallmark of both the original and recur-
rent lesions. Most questions regarding the origins of this
phenomenon remain unanswered, however.
DR. JEROME P. KASSIRER: Is there merit to our recommend-
ing that a patient have a second transplant when the first
transplant has shown recurrence of the original disease? What
are your thoughts about that, not only in the case of focal
sclerosis, but with other lesions as well?
DR. LEwis: There are reports in the literature of patients who
appear to have had a bona fide recurrence in the first transplant
but who did not get a recurrence of the lesion in the second or
third transplant [19, 25]. This is true of some patients with focal
and segmental glomerular sclerosis and hyalinosis. Recurrence
in the first transplant therefore is not an absolute contraindi-
cation to further transplants. We have no clear guidelines,
however, as instances of recurrent disease in transplants subse-
quent to the first also have been noted [26, 29].
DR. KASSIRER: What other renal diseases tend to recur in
transplants?
DR. LEWIS: Either histologic or clinical evidence of recur-
rence has been reported to be associated with a host of
glomerular lesions (Table 4). It is clear from the data reviewed
by Hamburger, Crosnier, and Noel [44] and from those collect-
ed by Cameron and Turner [23] that histologic evidence of
recurrence on renal biopsy is far more common than are
alterations shown on urinalysis or changes in renal function.
Graft failure due to recurrence of the glornerular lesion is even
more unusual. One therefore must be aware of the possibility of
recurrent glomerulonephritis, whether the original lesion is
FSGS/H, membranous glomerulonephritis, membranoprolifera-
tive glornerulonephritis, IgA glomerulopathy, or anti-glomeru-
lar basement membrane disease.
DR. MICHAEL MADAIO (Renal Service, NEMC): What guide-
lines do you use to decide when to perform renal transplanta-
tion in someone with known focal sclerosis or someone who has
had recurrent disease in a first transplant?
DR. LEWIS: lam not aware of any precise guidelines for that.
The data of Leumann et al, which I mentioned earlier, are the
most persuasive with regard to the use of the patient's original
course as a prognostic sign [22]. Another consideration is the
period of time that is allowed to elapse between the onset of
end-stage renal failure and the patient's transplant. Although
the existing literature contains little information regarding this
factor, an empiric suspicion exists that recurrent disease might
be more common if the pretransplant period is short.
DR. KASSIRER: How do you view the histologic designation of
focal sclerosis? Is there something quite specific, or is it only a
nonspecific response of the kidney to injury?
DR. VIVIAN PINN (Associate Professor of Pathology, Tufts
University School of Medicine): Focal segmental glomerulo-
sclerosis is often regarded as a specific entity when it is
associated with nephrotic syndrome. However, the lesion of
focal glomerulosclerosis itself may be seen with a variety of
disorders that lead to glomerular scarring, and therefore it
should be considered specific only in terms of the clinicopatho-
logic setting in which it is identified.
DR. JORDAN J. COHEN: Earlier in your discussion, Dr. Lewis,
you indicated that focal glomerulosclerosis and mesangial pro-
liferation were variants of minimal-change glomerulopathy.
Why do you regard them as variants rather than as separate
diseases?
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Fig. 3. Immunoglobulin M is deposited through the mesangium in a
patient who had the nephrotic syndrome associated with diffuse meson-
gialhypercellularity. The pathogenetic relevance of the presence of this
protein in these cases is debated [37].
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Table 4. Recurrent glomerulonephritis in renal transplants
Recurrent
Original glomerular lesion glomerulonephritisa
a Data from Ref. 44
b Data from Ref. 23.
Numerator reflects number of recurrences; denominator is the total number of patients who received transplants.
DR. LEwIs: There is currently debate regarding the pathoge-
netic interrelationships among these lesions. From the point of
view of the morphologists, I find it useful to consider all these
lesions part of the minimal-change glomerulopathy syndrome. I
support this approach because the finding of normal or essen-
tially normal glomeruli in a patient with massive proteinuria is
common to all three categories. But there is no compelling
evidence that indeed these are all variants of one disease
process.
I would take the argument one step further and suggest that
perhaps the lesion of focal and segmental glomerulosclerosis
and hyalinosis does not reflect a single pathogenetic process in
all cases. It is not obvious that this lesion, found for example in
a 5-year-old child who presents with the nephrotic syndrome
and a relatively short clinical course, represents the same
abnormality as an identical histopathologic lesion in a patient
with nephrotic syndrome relapsing over several years. Nor
does the lesion of FSGS/H in a heroin abuser necessarily reflect
the same pathogenesis. Thus, my consideration of these lesions
as variants of the minimal-change lesion merely refers to the
pathologic appearance one sees among nephrotic individuals
and does not imply pathogenetic significance.
DR. SUSAN Hou (Renal Service, NEMC): Does focal sclero-
sis tend to recur in transplanted kidneys when the original
lesion was associated with heroin abuse?
DR. LEWIs: To my knowledge there is no literature on this
subject. I personally believe that the disease noted in heroin
abusers and the lesion commonly associated with the idiopathic
nephrotic syndrome in children and young adults are not related
pathogenetically, but rather only are caused by disorders that
provoke a similar histopathologic lesion. I think it likely that the
heroin abuser who is capable of stopping the habit will not get a
recurrent lesion in a transplanted kidney.
DR. COHEN: As you noted, it's tempting to speculate, in view
of the extreme rapidity with which focal sclerosis can recur in
transplants, that the lesion is mediated by something in the
circulation. Has this clue prompted any investigative efforts in
this direction?
DR. LEWIS: To date, the strongest evidence has been derived
from the human experience with transplantation. No plasma or
lymphocyte transfer experiments have reproduced the lesion in
animals. Experimental evidence that lymphokines derived from
nephrotic patients can provoke proteinuria in experimental
animals has created some excitement [35, 361. However, this
phenomenon can be demonstrated with cell culture-derived
material from patients with a variety of lesions associated with
the nephrotic syndome, not just with those associated with
focal segmental glomerular sclerosis and hyalinosis or minimal-
change glomerulopathy. The significance of this type of experi-
ment therefore remains unknown.
DR. KASSIRER: In a case I discussed at a clinical pathologic
conference at the Massachusetts General Hospital [21], the
lesion of focal sclerosis and the heavy proteinuria reappeared
within days after the patient received a transplant. It is surpris-
ing to me that recurrence could be so rapid if an immunologic
mechanism is responsible.
DR. LEWIS: One can only speculate on this point. Certainly,
the lesion of recurrent anti-glomerular basement membrane
disease in transplants appears to be a rapidly developing one. If
sensitized cells are somehow involved in the pathogenesis of
this lesion, then the time course indeed could be very fast.
DR. ANDREW LEVEY (Renal Service, NEMC): In view of the
characteristic histologic changes that accompany vascular re-
jection, I am curious whether the presence of such changes can
help distinguish between transplant glomerulopathy and recur-
rence of focal sclerosis.
DR. LEWIS: I agree that this finding could provide some
valuable diagnostic evidence in a given case. However, the
coexistence of subacute or chronic vascular rejection and a
recurrence of a primary glomerular lesion must certainly be
common. I do not believe therefore that one could use this
finding as an absolute diagnostic aid.
DR. DAVID CAHAN (Chief of Nephrology, Faulkner Hospital,
Boston): First, does focal sclerosis recur in patients in whom
the lesion was originally associated with reflux nephropathy?
Second, can one justify performing a renal biopsy early in the
Histologic
evidence of
recurrenc&'
Clinical
evidence of
recurrence'
Focal and segmental
glomerular sclerosis 4/l4 6/31 6/31
Membranoproliferative
categories (excludes
dense-deposit disease) 7/40 16/27 16/27
Dense-deposit disease
(Type II MPGN) 8/11 22/22 3/22
Mesangial IgA glomerulopathy 9/20 7/13 7/13
Rapidly progressive GN 0/1
Membranous GN 0/2
Schonlein-Henoch purpura 1/6
Anti-GBM-mediated — 19/34 5/34
Systemic lupus erythematosis — 0/56 —
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course of what may be progressive renal insufficiency solely for
the purpose of establishing the likelihood of recurrent disease in
a possible future transplant?
DR. LEWIS: One of the patients studied by Aladjem et a! had a
renal transplant after developing renal failure from the focal
sclerosis and interstitial nephritis associated with reflux
nephropathy [34]. This patient had proteinuria with his original
disease. There was no evidence of recurrent disease in the
transplant.
Regarding your second question, I am inclined to base my
consideration for renal biopsy only on the diagnostic informa-
tion needed at the time the patient is being examined. Although
it might be useful information in the future, the existing data
regarding the attack rate of recurrent glomerulonephritis are not
compelling enough, in my opinion, to require this kind of
information in every patient.
Reprint requests to Dr. E. Lewis, Section o.f Nephro/ogy, Rush-
Presbyterian-St. Luke's Medical Center, /753 West Congress Parkway,
Chicago, Illinois 60612, USA
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